Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.

CONCLUSION: Introducing PCV13 as part of Mongolia's national programme appears to be highly cost-effective when compared to no vaccination and cost-saving from a societal perspective at vaccine purchase prices offered through Gavi. Notwithstanding uncertainties around some parameters, cost-effectiveness of PCV introduction for Mongolia remains robust over a range of conservative scenarios. Availability of high-quality national data would improve future economic analyses for vaccine introduction.
PMID: 28109706 [PubMed - as supplied by publisher]

Source: Vaccine - January 17, 2017 Category: Allergy & Immunology Authors: Sundaram N, Chen C, Yoong J, Luvsan ME, Fox K, Sarankhuu A, La Vincente S, Jit M Tags: Vaccine Source Type: research